SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience (NASDAQ: PURE) today announced that Cleveland Clinic has been issued an equity stake in FTA Therapeutics LLC, PURE’s pharmaceutical development partner for its patented silver dihydrogen citrate (SDC) antimicrobial.
